1360744-35-9

Upstream product

• 86988-35-4 3-benzoyl-1-[(6aR,8R,9R,9aS)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]pyrimidine-2,4(1H,3H)-dione 
• 1360744-34-8 2'-O-(N,N'-di-Boc-guanidinopropyl)-uridine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 1360744-33-7 2'-O-(N,N'-di-Boc-guanidinopropyl)-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-uridine 
• 1360744-32-6 2'-O-(aminopropyl)-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)-uridine 
• 864837-09-2 N³-benzoyl-2'-O-(2-cyanoethyl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 

Downstream Products

• 1360744-36-0 2'-O-(N,N'-di-Boc-guanidinopropyl)-5'-O-(4,4'-dimethoxytrityl)-uridine 3'-(cyanoethyl)-N,N-diisopropyl phosphoramidite 

Relevant academic research and scientific papers

Synthesis of 2′-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus

Synthetic RNAi activators have shown considerable potential for therapeutic application to silencing of pathology-causing genes. Typically these exogenous RNAi activators comprise duplex RNA of approximately 21 bp with 2 nt overhangs at the 3′ ends. To im